キイトルーダの市場規模、シェア、成長分析、支払者別、流通チャネル別、用途別、地域別 - 産業予測、2025年～2032年

キイトルーダの世界市場規模は2023年に282億米ドルと評価され、2024年の306億5,000万米ドルから2032年までには597億5,000万米ドルに成長し、予測期間（2025年～2032年）のCAGRは8.7%で成長する見通しです。

世界のキイトルーダ市場は、肺がん、メラノーマ、胃がん、子宮頸がん、子宮内膜がんなど、さまざまながんで承認された適応症の拡大が大きな成長の原動力となっています。早期の疾患や併用療法において一貫した臨床効果が確認されていることから、ヘルスケアプロバイダー間での採用が進んでいます。メルクは皮下注製剤の導入を予定しており、これにより患者の利便性が向上し、投与が合理化されるため、特許切れが迫っているとはいえ、市場シェアが高まることが予想されます。とはいえ、同市場は課題に直面しており、特に独占権の喪失やバイオシミラー医薬品の競合品の出現が予想され、先進国市場と新興国市場の双方でその軌道に影響を与える可能性があります。加えて、治療費の高騰や支払側の抵抗が販売量の伸びを阻害する可能性もあり、積極的なシェア獲得から進化する情勢の戦略的管理への転換が迫られています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主要な市場の考察

• 主要な成功要因
• 競合の程度
• 主要な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 顧客購買行動分析

世界のキイトルーダの市場規模：支払者別・CAGR（2025年～2032年）

• 市場概要
• 商業/個人
• 公共

世界のキイトルーダの市場規模：流通チャネル別・CAGR（2025年～2032年）

• 市場概要
• 病院薬局
• 専門薬局

世界のキイトルーダの市場規模：用途別・CAGR（2025年～2032年）

• 市場概要
• 肺がん
• 乳がん
• 黒色腫
• ホジキンリンパ腫
• 頭頸部がん
• 胃がん
• 尿路上皮がん
• その他

世界のキイトルーダの市場規模・CAGR（2025年～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022年～2024年）

主要企業プロファイル

• Merck & Co. Inc.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Roche Holding AG
• Pfizer Inc.
• Novartis AG
• GlaxoSmithKline
• Eisai Co., Ltd.
• Innovent Biologics
• BeiGene
• Biomab
• Aspen Pharmacare
• Johnson & Johnson
• Eli Lilly and Company
• AbbVie Inc.

結論と提言

Global Keytruda Market size was valued at USD 28.2 billion in 2023 and is poised to grow from USD 30.65 billion in 2024 to USD 59.75 billion by 2032, growing at a CAGR of 8.7% during the forecast period (2025-2032).

The global Keytruda market is experiencing significant growth driven by its expanding range of approved indications in various cancers, including lung, melanoma, gastric, cervical, and endometrial. The consistent clinical efficacy observed in early-stage diseases and in combination therapies enhances its adoption among healthcare providers. Merck's anticipated introduction of a subcutaneous formulation is set to improve patient convenience and streamline dosing, thus boosting its market share, even as patent expiration looms. Nonetheless, the market faces challenges, notably the anticipated loss of exclusivity and the emergence of biosimilar competitors, which may impact its trajectory in both developed and emerging markets. Additionally, high treatment costs and payer resistance could inhibit volume growth, prompting a shift in focus from aggressive share acquisition to strategic management of the evolving landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Keytruda market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Keytruda Market Segments Analysis

Global Keytruda Market is segmented by Payer, Distribution Channel, Application and region. Based on Payer, the market is segmented into Commercial/Private and Public. Based on Distribution Channel, the market is segmented into Hospital Pharmacy and Specialty Pharmacy. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma, Head & Neck Cancer, Gastric Cancer, Urothelial Cancer and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Keytruda Market

Keytruda's impressive expansion across various cancer types, such as non-small cell lung cancer, melanoma, head and neck cancer, endometrial cancer, and triple-negative breast cancer, has solidified its position in the global market. Each new regulatory approval enhances patient access and boosts physician confidence, positioning Keytruda as a foundational therapy in oncology treatment protocols. The growing significance of PD-1 inhibitors, including Keytruda, within precision oncology is facilitating its application in early-stage and adjuvant treatment settings, thereby ensuring sustained revenue growth and widespread adoption in both developed and emerging markets. This multifaceted approach underscores Keytruda's pivotal role in contemporary cancer care.

Restraints in the Global Keytruda Market

A significant obstacle to the future success of Keytruda lies in the impending expiration of its primary patents in major markets, which could adversely affect its long-term viability. Despite Merck's efforts to extend Keytruda's market presence, the loss of exclusivity is likely to exert pressure on pricing, reimbursement strategies, and overall market share. This challenge is particularly pronounced in high-volume therapeutic areas, such as non-small cell lung cancer, where competitive dynamics intensify, and insurers increasingly seek cost containment measures. Such factors may hinder Keytruda's ability to maintain its established position in the global market.

Market Trends of the Global Keytruda Market

The Global Keytruda market is witnessing a significant trend towards early-stage treatment and the expansion of adjuvant therapy, driven by Merck's strategic shift in focus. This transition is fueled by recent approvals from regulatory agencies in the U.S., Europe, and Asia for Keytruda's use in earlier stages of melanoma, non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). Strong clinical data further supports this movement, highlighting improvements in disease-free survival (DFS) and long-term cost-effectiveness. Consequently, this trend not only prolongs therapy duration for patients but also solidifies Merck's competitive advantage by embedding Keytruda deeper into established oncology guidelines.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Keytruda Market Size by Payer & CAGR (2025-2032)

• Market Overview
• Commercial/Private
• Public

Global Keytruda Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Specialty Pharmacy

Global Keytruda Market Size by Application & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Melanoma
• Hodgkin Lymphoma
• Head & Neck Cancer
• Gastric Cancer
• Urothelial Cancer
• Others

Global Keytruda Market Size & CAGR (2025-2032)

• North America (Payer, Distribution Channel, Application)
  • US
  • Canada
• Europe (Payer, Distribution Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Payer, Distribution Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Payer, Distribution Channel, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Payer, Distribution Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomab
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspen Pharmacare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations